Zoll gains FDA OK for public use defibrillator:
This article was originally published in Clinica
Executive Summary
Zoll Medical has gained FDA 510(k) approval to market its automated external defibrillator in the US for the emergency treatment of sudden cardiac arrest. The battery-powered Zoll AED Plus device, which features simple, step by step illustrations and audio coaching, is designed to be easy to use for the lay person to assist heart attack victims. It is the first AED to use a single electrode pad that is easy to position on the victim's body, said the Burlington, Massachusetts firm.
You may also be interested in...
IPO Year In Review: Record-Year Bodes Well For 2021, And For More SPACs
Biopharma was an attractive investment in 2020 and fundamentals are unchanged in 2021, including the pandemic’s work-at-home requirements, which allowed more companies to go public faster.
Abbott Capitalizes On Pandemic Testing Boom; Device Sales Stay Almost Flat
Abbott reported almost 28% revenue growth in the fourth quarter led by the exploding demand for COVID-19 tests and continued success of its FreeStyle Libre continuous glucose monitor.
Agios’ Mitapivat Shows Improvement In Regularly Transfused PKD Patients
While representing a smaller population, the ACTIVATE-T trial targeted patients seen as having greater unmet need.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: